Dexcom raises outlook as 15-day CGM adoption and access expand

Transcript intelligence

What changed

Compared with the prior-quarter analysis, management's stance shifted from maintaining guidance to raising full-year revenue and margin guidance. The current analysis adds Q2 margin expansion, progress toward 15-day conversion, CONNECT trial evidence for type 2 non-insulin patients, the Nutrisense acquisition, and Ireland capacity expansion.

Guidance delta

Management raised full-year revenue and margin guidance after Q2, according to the supplied earnings analysis.

Key takeaways

• Management said Q2 revenue grew 13% year over year to $1.31 billion, with gross margin expanding to 64.1%.
• The G7 15-day sensor rollout was described as on track for approximately 50% U.S. customer conversion by year-end.
• The CONNECT trial and expanded payer access support management's push for broader type 2 non-insulin coverage.
• International launches and approvals continued, while Nutrisense adds nutrition insights to the Dexcom ecosystem.
• The Ireland manufacturing ramp and the timing of CMS coverage remain execution variables.

Management priorities

• Scale the G7 15-day system globally and pursue approximately 50% U.S. conversion by year-end.
• Advance CMS coverage for type 2 non-insulin patients using CONNECT data.
• Expand international access and launches, including in Canada and Europe.
• Integrate Nutrisense nutrition insights into Stello and the broader Dexcom ecosystem.
• Build Ireland manufacturing capacity and develop the future G8 sensor.